You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

annexin A2

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gestational Diabetes, Maternal Complication of Pregnancy Trial in New Haven (Continuous Glucose Monitor, Routine Care)

Recruiting
  • Gestational Diabetes
  • Maternal Complication of Pregnancy
  • Continuous Glucose Monitor
  • Routine Care
  • New Haven, Connecticut
    Yale University
Feb 1, 2022

Mitapivat in Subjects With Sickle Cell Disease

Enrolling by invitation
  • Sickle Cell Anemia
  • +7 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) Trial in La Jolla, Philadelphia (RP-A601)

    Not yet recruiting
    • PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
    • RP-A601
    • La Jolla, California
    • +1 more
    May 22, 2023

    CYP1A2, ABCB1, CYP2C9 and Plasma Concentration of Agomelatine in

    Not yet recruiting
    • Polymorphism, Genetic
    • +5 more
      • (no location specified)
      Nov 3, 2023

      Blood Metabolic Markers in Type 2 Diabetes Mellitus of Different

      Not yet recruiting
      • Diabetes Mellitus, Type 2
      • No intervention
      • Jinan, Shandong, China
        Peng Wu
      Nov 24, 2023

      Diabete Type 2, Obesity Trial in Orlando (HU6)

      Not yet recruiting
      • Diabete Type 2
      • Obesity
      • Orlando, Florida
        AdventHealth Translational Research Institute
      Oct 23, 2023

      HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

      Not yet recruiting
      • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
      • SHR-A1811
      • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
      • (no location specified)
      Nov 6, 2023

      Triple-negative Breast Cancer Trial in Shanghai (A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, B1: TROP2 ADC)

      Not yet recruiting
      • Triple-negative Breast Cancer
      • A1: SHR-A1811
      • +11 more
      • Shanghai, China
        Fudan University Shanghai Cancer Center
      Feb 19, 2023

      Advanced Solid Tumor, CDKN2A, NSCLC Trial (Milademetan, Atezolizumab)

      Withdrawn
      • Advanced Solid Tumor
      • +9 more
      • (no location specified)
      Oct 16, 2023

      Natural History Study for Charcot Marie Tooth Disease

      Recruiting
      • Charcot-Marie-Tooth Disease
      • +47 more
        • New York, New York
          Hereditary Neuropathy Foundation
        Jun 12, 2023

        Type2diabetes, Obesity, Diet, Healthy Trial in Milano (Vegetarian Meal)

        Recruiting
        • Type2diabetes
        • +3 more
        • Vegetarian Meal
        • Milano, Italy
          IRCCS Ospedale San Raffaele
        Nov 28, 2023

        NSCLC, Urothelial Cancer Trial in Worldwide (Avelumab 800 mg in combination with pemetrexed / carboplatin, Avelumab 800 mg in

        Active, not recruiting
        Has Results
        • Non-small Cell Lung Cancer
        • Urothelial Cancer
        • Avelumab 800 mg in combination with pemetrexed / carboplatin
        • +3 more
        • Tucson, Arizona
        • +45 more
        Oct 13, 2022

        Healthy Participants Trial (mPnC candidate, mPnC control)

        Not yet recruiting
        • Healthy Participants
        • mPnC candidate
        • mPnC control
        • (no location specified)
        Oct 30, 2023

        Healthy Trial in Glendale (Y-2 Sublingual Tablet, Placebo)

        Not yet recruiting
        • Healthy
        • Y-2 Sublingual Tablet
        • Placebo
        • Glendale, California
          Parexel International Los Angeles Early Phase Clinical Unit
        Jul 10, 2023

        Chronic Hepatitis B Trial run by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (VIR-2218 and

        Not yet recruiting
        • Chronic Hepatitis B
        • VIR-2218 and peginterferon alfa-2a
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Oct 27, 2023

        Type 2 Diabetes Treated With Insulin, Diet Habit Trial (Oviva programme, Usual care)

        Not yet recruiting
        • Type 2 Diabetes Treated With Insulin
        • Diet Habit
        • Oviva programme
        • Usual care
        • (no location specified)
        Nov 3, 2023

        Long-Term Development of Muscular Dystrophy Outcome Assessments

        Not yet recruiting
        • LGMD1A
        • +33 more
          • Richmond, Virginia
            Virginia Commonwealth University
          Aug 3, 2023

          Atopic Dermatitis, Type 1 Hypersensitivity Trial in Australia, Puerto Rico, United States (STMC-103H, Placebo)

          Recruiting
          • Atopic Dermatitis
          • Type 1 Hypersensitivity
          • STMC-103H
          • Placebo
          • Tucson, Arizona
          • +25 more
          Dec 1, 2022

          Parent-Child Relations, Parenting Trial in Stockholm (ABC 0-2 years, waiting list)

          Completed
          • Parent-Child Relations
          • Parenting
          • ABC 0-2 years
          • waiting list
          • Stockholm, Sweden
            PLUS
          Sep 7, 2023

          COVID-19 Vaccine, COVID-19 Trial in Bangkok (50 µg Baiya SARS-CoV-2 Vax 2, Placebo)

          Not yet recruiting
          • COVID-19 Vaccine
          • COVID-19
          • 50 μg Baiya SARS-CoV-2 Vax 2
          • Placebo
          • Bangkok, Thailand
            Queen Saovabha Memorial Institute
          May 23, 2023

          Type 2 Diabetes Trial in Herlev (Person-centred culturally sensitive course of treatment)

          Recruiting
          • Type 2 Diabetes
          • Person-centred culturally sensitive course of treatment
          • Herlev, Denmark
            Steno Diabetes Center Copenhagen
          Nov 27, 2023

          Tobacco Use Disorder, Diabetes, Type 2 Trial in Sevilla (Control group (waiting list), Cognitive Behavioral Treatment (CBT) for

          Not yet recruiting
          • Tobacco Use Disorder
          • Diabetes Mellitus, Type 2
          • Control group (waiting list)
          • +2 more
          • Sevilla, Spain
            Carla López Núñez
          May 22, 2023

          Immunogenicity, Safety Trial (Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2;)

          Not yet recruiting
          • Immunogenicity
          • Safety
          • Phase II:SWIM816;SARS-Cov-2;
          • +3 more
          • (no location specified)
          Jun 18, 2023

          Peripheral Circulatory Disorder Due to Type 2 Diabetes Trial (Buerger-Allen Exercise)

          Not yet recruiting
          • Peripheral Circulatory Disorder Due to Type 2 Diabetes Mellitus
          • Buerger-Allen Exercise
          • (no location specified)
          Sep 26, 2023

          Pediatric Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations

          Not yet recruiting
          • Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF)
          • +2 more
            • (no location specified)
            Aug 25, 2023